S&P 500   5,056.06 (-0.11%)
DOW   37,813.03 (+0.21%)
QQQ   430.82 (-0.06%)
AAPL   169.07 (-2.10%)
MSFT   415.14 (+0.36%)
META   500.34 (+0.02%)
GOOGL   154.59 (-0.17%)
AMZN   183.27 (-0.19%)
TSLA   156.07 (-3.35%)
NVDA   873.26 (+1.54%)
AMD   162.84 (+1.57%)
NIO   3.86 (-0.77%)
BABA   69.92 (-0.99%)
T   15.98 (-1.60%)
F   12.12 (-0.90%)
MU   121.02 (-0.29%)
GE   155.42 (+1.12%)
CGC   6.80 (-2.58%)
DIS   113.68 (+0.65%)
AMC   2.80 (+13.36%)
PFE   25.74 (-0.66%)
PYPL   63.57 (+0.09%)
XOM   118.23 (-1.21%)
S&P 500   5,056.06 (-0.11%)
DOW   37,813.03 (+0.21%)
QQQ   430.82 (-0.06%)
AAPL   169.07 (-2.10%)
MSFT   415.14 (+0.36%)
META   500.34 (+0.02%)
GOOGL   154.59 (-0.17%)
AMZN   183.27 (-0.19%)
TSLA   156.07 (-3.35%)
NVDA   873.26 (+1.54%)
AMD   162.84 (+1.57%)
NIO   3.86 (-0.77%)
BABA   69.92 (-0.99%)
T   15.98 (-1.60%)
F   12.12 (-0.90%)
MU   121.02 (-0.29%)
GE   155.42 (+1.12%)
CGC   6.80 (-2.58%)
DIS   113.68 (+0.65%)
AMC   2.80 (+13.36%)
PFE   25.74 (-0.66%)
PYPL   63.57 (+0.09%)
XOM   118.23 (-1.21%)
S&P 500   5,056.06 (-0.11%)
DOW   37,813.03 (+0.21%)
QQQ   430.82 (-0.06%)
AAPL   169.07 (-2.10%)
MSFT   415.14 (+0.36%)
META   500.34 (+0.02%)
GOOGL   154.59 (-0.17%)
AMZN   183.27 (-0.19%)
TSLA   156.07 (-3.35%)
NVDA   873.26 (+1.54%)
AMD   162.84 (+1.57%)
NIO   3.86 (-0.77%)
BABA   69.92 (-0.99%)
T   15.98 (-1.60%)
F   12.12 (-0.90%)
MU   121.02 (-0.29%)
GE   155.42 (+1.12%)
CGC   6.80 (-2.58%)
DIS   113.68 (+0.65%)
AMC   2.80 (+13.36%)
PFE   25.74 (-0.66%)
PYPL   63.57 (+0.09%)
XOM   118.23 (-1.21%)
S&P 500   5,056.06 (-0.11%)
DOW   37,813.03 (+0.21%)
QQQ   430.82 (-0.06%)
AAPL   169.07 (-2.10%)
MSFT   415.14 (+0.36%)
META   500.34 (+0.02%)
GOOGL   154.59 (-0.17%)
AMZN   183.27 (-0.19%)
TSLA   156.07 (-3.35%)
NVDA   873.26 (+1.54%)
AMD   162.84 (+1.57%)
NIO   3.86 (-0.77%)
BABA   69.92 (-0.99%)
T   15.98 (-1.60%)
F   12.12 (-0.90%)
MU   121.02 (-0.29%)
GE   155.42 (+1.12%)
CGC   6.80 (-2.58%)
DIS   113.68 (+0.65%)
AMC   2.80 (+13.36%)
PFE   25.74 (-0.66%)
PYPL   63.57 (+0.09%)
XOM   118.23 (-1.21%)
Free Trial

Teva Pharmaceutical Industries (TEVA) Stock Forecast & Price Target

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)
Free teva Stock Alerts
$13.11
-0.12 (-0.91%)
(As of 02:27 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

Teva Pharmaceutical Industries Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 10 Analyst Ratings

Analysts' Consensus Price Target

$13.78
5.09% Upside
High Forecast$19.00
Average Forecast$13.78
Low Forecast$10.00
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Reduce
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$13.78$13.78$12.43$10.75
Predicted Upside5.09% Upside26.03% Upside27.78% Upside13.09% Upside
Get Teva Pharmaceutical Industries Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

TEVA Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

TEVA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Teva Pharmaceutical Industries Stock vs. The Competition

TypeTeva Pharmaceutical IndustriesMedical CompaniesS&P 500
Consensus Rating Score
2.70
2.68
2.49
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside5.17% Upside895.75% Upside11.91% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/8/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderweight ➝ Neutral$14.00+2.12%
2/12/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Overweight$12.00 ➝ $19.00+58.20%
2/5/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral ➝ Neutral$10.00 ➝ $11.00-10.13%
2/5/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$15.00 ➝ $17.00+38.32%
1/23/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$10.00 ➝ $14.00+21.85%
12/18/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$13.00+30.26%
11/27/2023UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeNeutral ➝ Buy$11.00 ➝ $13.00+36.13%
9/8/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$12.00 ➝ $13.00+36.13%
5/25/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageEqual Weight$10.00+32.10%
5/18/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeIn-Line ➝ Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:44 PM ET.

TEVA Price Target - Frequently Asked Questions

What is Teva Pharmaceutical Industries's consensus rating and price target?

According to the issued ratings of 10 analysts in the last year, the consensus rating for Teva Pharmaceutical Industries stock is Moderate Buy based on the current 3 hold ratings and 7 buy ratings for TEVA. The average twelve-month price prediction for Teva Pharmaceutical Industries is $13.78 with a high price target of $19.00 and a low price target of $10.00. Learn more on TEVA's analyst rating history.

Do Wall Street analysts like Teva Pharmaceutical Industries more than its competitors?

Analysts like Teva Pharmaceutical Industries more than other Medical companies. The consensus rating score for Teva Pharmaceutical Industries is 2.70 while the average consensus rating score for medical companies is 2.68. Learn more on how TEVA compares to other companies.

Is Teva Pharmaceutical Industries being upgraded by Wall Street analysts?

Over the previous 90 days, Teva Pharmaceutical Industries's stock had 3 upgrades by analysts.

Does Teva Pharmaceutical Industries's stock price have much upside?

According to analysts, Teva Pharmaceutical Industries's stock has a predicted upside of 26.03% based on their 12-month stock forecasts.

What analysts cover Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has been rated by Barclays, Jefferies Financial Group, JPMorgan Chase & Co., Piper Sandler, and The Goldman Sachs Group in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:TEVA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
The “Perfect Storm” for Gold
Gold Safe Exchange
Top 5 AI Stocks to Buy for 2024
Market Moving Trends